KalVista Pharmaceuticals (KALV) reported Wednesday a net loss of $2.03 per diluted share for the eight months ended Dec. 31, narrowing from the $2.30 net loss per share a year earlier.
Product revenue for the period was $49.1 million, compared with zero revenue a year earlier.
Analysts' estimates were unavailable for comparison.
The company said the eight-month period through ended Dec. 31 is a transition period as it changed its fiscal year to end Dec. 31 from April 30 previously.
Shares of KalVista Pharmaceuticals were up more than 2% premarket Wednesay.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments